TB-500
Women's HealthWomen's-health applications of TB-500 require explicit attention to cyclical hormonal context, contraceptive and pregnancy considerations, and — for users in perimenopause or postmenopause — integration with HRT. Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool This influences cell migration during repair, angiogenesis, and stem-cell mobilisation. Acts systemically when injected anywhere, unlike many peptides whose effects are local.. Dosing at 2-5 mg 1-2x weekly subq (loading phase); maintenance lower via subq/im with cycle-phase-aware tracking is the standard protocol for premenopausal users.
Key Takeaways
Female-physiology lens: TB-500 response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause. Mechanism: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default. Female dose: 2-5 mg 1-2x weekly subq (loading phase); maintenance lower via subq/im; cycle-phase tracking for 1-2 cycles. Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.
Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. This influences cell migration during repair, angiogenesis, and stem-cell mobilisation. Acts systemically when injected anywhere, unlike many peptides whose effects are local. For women's-health applications, the mechanism is evaluated against cyclical context, fertility implications, bone remodelling, and cardiovascular tone. TB-500's contribution to each varies; the subsections below work through these in turn.
Perimenopause and menopause integration
For women in the perimenopausal or post-menopausal window, TB-500 is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.
Cyclical and hormonal context
Female physiology is cyclical in a way that male physiology is not, and TB-500's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.
Bone density and cardiovascular signalling
Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. TB-500's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.
For sleep in female users, TB-500 is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
Skin Health is one of the dimensions on which women track TB-500 response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.
In the perimenopausal window, TB-500 for cycle support produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.
For pcos support in female users, TB-500 is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 2-5 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1-5 mg | 4–6 weeks initial cycle |
| Women's Health focus | SubQ | 2-5 mg | 1-2x weekly SubQ (loading phase); maintenance lower |
| Maintenance phase | SubQ | 1-5 mg | Ongoing with periodic pauses |
Dose timing for TB-500 is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
TB-500 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.
- TB-500 + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with TB-500's mechanism in female physiology protocols.
- TB-500 + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with TB-500's mechanism in female physiology protocols.
- TB-500 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with TB-500's mechanism in female physiology protocols.
- TB-500 + Epithalon: Identified by Khavinson in St. Pairs naturally with TB-500's mechanism in female physiology protocols.
Generally well tolerated. Limited human safety data. Avoid in active cancer.
Lens-specific safety considerations for female physiology use of TB-500: Generally well tolerated. Limited human safety data. Avoid in active cancer. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | Women's Health |
| Oxytocin | Posterior pituitary nonapeptide | ~1-6 min plasma; CNS longer | The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
How will TB-500 interact with my cycle?
Best monitoring labs for female users?
Is TB-500 appropriate during perimenopause?
Can I use TB-500 alongside HRT?
What does TB-500 stack well with?
What is the evidence base for TB-500?
Start a TB-500 Protocol
Alukard provides physician-supervised women's health protocols with GMP-certified TB-500 and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
Get ProtocolQuick Facts
- Molecular weight
- 888-1717 Da (depending on form)
- Sequence length
- 17 aa
- Half-life
- ~2-3 days
- WADA
- Banned (S0)
- FDA
- Unapproved
- Research
- Preclinical + veterinary clinical (equine)
Stack Partners
All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for TB-500 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Female Physiology Protocol for TB-500
Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.
HIPAA Compliant · GMP Certified · Physician Supervised